Sol Gel Technologies Ltd

General ticker "SLGL" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $14.2M

Sol Gel Technologies Ltd does not follow the US Stock Market performance with the rate: -32.4%.

Estimated limits based on current volatility of 43.2%: low 0.85$, high 1.23$

Factors to consider:

  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [0.81$, 2.25$]
  • 2024-12-30 to 2025-12-30 estimated range: [0.92$, 2.34$]

Financial Metrics affecting the SLGL estimates:

  • Negative: Non-GAAP EPS, $ of -1.01 <= 0.10
  • Negative: Operating profit margin, % of -94.96 <= 1.03
  • Negative: Operating cash flow per share per price, % of -35.50 <= 2.35
  • Positive: Interest expense per share, $ of 0 <= 0
  • Positive: -0.96 < Investing cash flow per share, $ of -0.36
  • Positive: Industry inventory ratio change (median), % of -2.41 <= -0.39
  • Negative: negative Net income
  • Negative: Industry earnings per price (median), % of -15.01 <= 1.31

Similar symbols

Short-term SLGL quotes

Long-term SLGL plot with estimates

Financial data

YTD 2022-12-31 2023-12-31
Operating Revenue $3.88MM $1.55MM
Operating Expenses $20.13MM $30.86MM
Operating Income $-16.24MM $-29.30MM
Non-Operating Income $1.32MM $2.07MM
R&D Expense $12.68MM $23.54MM
Income(Loss) $-14.92MM $-27.24MM
Taxes $-1.32MM $0.00MM
Profit(Loss) $-13.60MM $-27.24MM
Stockholders Equity $42.21MM $38.64MM
Inventory $0.00MM $0.00MM
Assets $46.63MM $45.29MM
Operating Cash Flow $-9.48MM $-17.73MM
Capital expenditure $0.17MM $0.13MM
Investing Cash Flow $1.70MM $-9.74MM
Financing Cash Flow $0.01MM $21.81MM
Earnings Per Share* $-0.59 $-1.01

* EPS are Split Adjusted, recent splits may be reflected with a delay.